Literature DB >> 22342990

Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma.

Norie Sawada1, Manami Inoue, Motoki Iwasaki, Shizuka Sasazuki, Taichi Shimazu, Taiki Yamaji, Ribeka Takachi, Yasuhito Tanaka, Masashi Mizokami, Shoichiro Tsugane.   

Abstract

BACKGROUND & AIMS: Fish is a rich source of n-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA). Although consumption of fish and n-3 PUFA has been reported to protect against the development of some types of cancer, little is known about its association with hepatocellular carcinoma (HCC).
METHODS: We investigated the association between fish and n-3 PUFA consumption and HCC incidence (n = 398) in a population-based prospective cohort study of 90,296 Japanese subjects (aged, 45-74 y). Hazard ratios and 95% confidence intervals (CIs) for the highest vs the lowest quintile were estimated from multivariable adjusted Cox proportional hazards regression models. We also conducted subanalyses of subjects with known hepatitis B virus (HBV) or hepatitis C virus (HCV) status, and of subjects who were anti-HCV and/or hepatitis B surface antigen positive. All tests of statistical significance were 2-sided.
RESULTS: Among all subjects, consumption of n-3 PUFA-rich fish and individual n-3 PUFAs was associated inversely with HCC, in a dose-dependent manner. Hazard ratios for the highest vs lowest quintiles were 0.64 (95% CI, 0.42-0.96) for n-3 PUFA-rich fish, 0.56 (95% CI, 0.36-0.85) for EPA, 0.64 (95% CI, 0.41-0.98) for DPA, and 0.56 (95% CI, 0.35-0.87) for DHA. These inverse associations were similar irrespective of HCV or HBV status.
CONCLUSIONS: Consumption of n-3 PUFA-rich fish or n-3 PUFAs, particularly EPA, DPA, and DHA, appears to protect against the development of HCC, even among subjects with HBV and/or HCV infection.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22342990     DOI: 10.1053/j.gastro.2012.02.018

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  68 in total

1.  Fish consumption doesn't reduce the risk of hepatocellular carcinoma.

Authors:  Cheng-Bao Wang; Qing-Xia Fu; Hai-Yan Liu; Rui Wang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver Tumors in Rats.

Authors:  Xiaodong Wen; Lacy Reynolds; Rohit S Mulik; Soo Young Kim; Tim Van Treuren; Liem H Nguyen; Hao Zhu; Ian R Corbin
Journal:  Gastroenterology       Date:  2015-10-17       Impact factor: 22.682

3.  Comparison between the impact of fermented and unfermented soy intake on the risk of liver cancer: the JPHC Study.

Authors:  Sarah Krull Abe; Norie Sawada; Junko Ishihara; Ribeka Takachi; Nagisa Mori; Taiki Yamaji; Taichi Shimazu; Atsushi Goto; Motoki Iwasaki; Manami Inoue; Shoichiro Tsugane
Journal:  Eur J Nutr       Date:  2020-07-27       Impact factor: 5.614

4.  Dietary Patterns and Risk of Hepatocellular Carcinoma Among U.S. Men and Women.

Authors:  Yanan Ma; Wanshui Yang; Tracey G Simon; Stephanie A Smith-Warner; Teresa T Fung; Jing Sui; Dawn Chong; Trang VoPham; Jeffrey A Meyerhardt; Deliang Wen; Edward L Giovannucci; Andrew T Chan; Xuehong Zhang
Journal:  Hepatology       Date:  2019-03-05       Impact factor: 17.425

5.  Low-density lipoprotein-mediated delivery of docosahexaenoic acid selectively kills murine liver cancer cells.

Authors:  Lacy Reynolds; Rohit S Mulik; Xiaodong Wen; Archana Dilip; Ian R Corbin
Journal:  Nanomedicine (Lond)       Date:  2014-01-07       Impact factor: 5.307

Review 6.  Chemopreventive strategies in hepatocellular carcinoma.

Authors:  Siddharth Singh; Preet Paul Singh; Lewis R Roberts; William Sanchez
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-08-13       Impact factor: 46.802

Review 7.  Pharmacological agents for NASH.

Authors:  Vlad Ratziu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-10-15       Impact factor: 46.802

8.  Nonalcoholic fatty liver disease: from lipid profile to treatment.

Authors:  Kouichi Miura; Hirohide Ohnishi
Journal:  Clin J Gastroenterol       Date:  2012-06-17

Review 9.  Intake of fish and long-chain n-3 polyunsaturated fatty acids and risk of diseases in a Japanese population: a narrative review.

Authors:  Mitsumasa Umesawa; Kazumasa Yamagishi; Hiroyasu Iso
Journal:  Eur J Clin Nutr       Date:  2020-09-16       Impact factor: 4.016

Review 10.  Nutrition and metabolism in hepatocellular carcinoma.

Authors:  Robert J Smith
Journal:  Hepatobiliary Surg Nutr       Date:  2013-04       Impact factor: 7.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.